BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

396 related articles for article (PubMed ID: 29197108)

  • 1. Refining a Claims-based Algorithm to Estimate Biologic Medication Effectiveness and Cost per Effectively Treated Patient with Rheumatoid Arthritis.
    Popp RA; Rascati K; Davis M; Patel U
    Pharmacotherapy; 2018 Feb; 38(2):172-180. PubMed ID: 29197108
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost and effectiveness of biologics for rheumatoid arthritis in a commercially insured population.
    Curtis JR; Chastek B; Becker L; Quach C; Harrison DJ; Yun H; Joseph GJ; Collier DH
    J Manag Care Spec Pharm; 2015 Apr; 21(4):318-29. PubMed ID: 25803765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estimating effectiveness and cost of biologics for rheumatoid arthritis: application of a validated algorithm to commercial insurance claims.
    Curtis JR; Schabert VF; Harrison DJ; Yeaw J; Korn JR; Quach C; Yun H; Joseph GJ; Collier DH
    Clin Ther; 2014 Jul; 36(7):996-1004. PubMed ID: 25012729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of a validated algorithm to estimate the annual cost of effective biologic treatment for rheumatoid arthritis.
    Curtis JR; Schabert VF; Yeaw J; Korn JR; Quach C; Harrison DJ; Yun H; Joseph GJ; Collier D
    J Med Econ; 2014 Aug; 17(8):555-66. PubMed ID: 24754646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost per patient-year in response using a claims-based algorithm for the 2 years following biologic initiation in patients with rheumatoid arthritis.
    Bonafede M; Johnson BH; Princic N; Shah N; Harrison DJ
    J Med Econ; 2015 May; 18(5):376-89. PubMed ID: 25530318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and Costs Among Rheumatoid Arthritis Patients Treated with Targeted Immunomodulators Using Real-World U.S. Data.
    Gharaibeh M; Bonafede M; McMorrow D; Hernandez EJM; Stolshek BS
    J Manag Care Spec Pharm; 2020 Aug; 26(8):1039-1049. PubMed ID: 32715967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medication effectiveness with the use of tumor necrosis factor inhibitors among Texas Medicaid patients diagnosed with rheumatoid arthritis.
    Oladapo A; Barner JC; Lawson KA; Novak S; Rascati KL; Richards KM; Harrison DJ
    J Manag Care Spec Pharm; 2014 Jul; 20(7):657-67. PubMed ID: 24967519
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biologic Cost per Effectively Treated Rheumatoid Arthritis Patient in a Large Managed Care Population: A Retrospective Cohort Study.
    Gu T; Shah N; Deshpande G; Tang DH; Eisenberg DF; Harrison DJ
    J Health Econ Outcomes Res; 2016; 3(2):122-131. PubMed ID: 37663319
    [No Abstract]   [Full Text] [Related]  

  • 9. Two-year adherence and costs for biologic therapy for rheumatoid arthritis.
    Stolshek BS; Wade S; Mutebi A; De AP; Wade RL; Yeaw J
    Am J Manag Care; 2018 Jul; 24(8 Spec No.):SP315-SP321. PubMed ID: 30020744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost of biologic treatment persistence or switching in rheumatoid arthritis.
    Gu T; Mutebi A; Stolshek BS; Tan H
    Am J Manag Care; 2018 Jul; 24(8 Spec No.):SP338-SP345. PubMed ID: 30020745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estimating the response and economic burden of rheumatoid arthritis patients treated with biologic disease-modifying antirheumatic drugs in Taiwan using the National Health Insurance Research Database (NHIRD).
    Shi Q; Li KJ; Treuer T; Wang BCM; Gaich CL; Lee CH; Wu WS; Furnback W; Tang CH
    PLoS One; 2018; 13(4):e0193489. PubMed ID: 29624580
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The comparative effectiveness of biologics among older adults and disabled rheumatoid arthritis patients in the Medicare population.
    Yun H; Xie F; Delzell E; Chen L; Yang S; Saag KG; Joseph G; Harrison D; Curtis JR
    Br J Clin Pharmacol; 2015 Dec; 80(6):1447-57. PubMed ID: 26130274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost of biologics per treated patient across immune-mediated inflammatory disease indications in a pharmacy benefit management setting: a retrospective cohort study.
    Wu N; Lee YC; Shah N; Harrison DJ
    Clin Ther; 2014 Aug; 36(8):1231-41, 1241.e1-3. PubMed ID: 25062652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness and healthcare costs among stabilised rheumatoid arthritis patients with dose reduction of adalimumab or etanercept in real world.
    Yang M; Galebach PJ; Signorovitch JE; Garg V
    Clin Exp Rheumatol; 2017; 35(5):791-798. PubMed ID: 28339358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment patterns and annual biologic costs in US veterans with rheumatic conditions or psoriasis.
    Sauer BC; Teng CC; He T; Leng J; Lu CC; Walsh JA; Shah N; Harrison DJ; Tang DH; Cannon GW
    J Med Econ; 2016; 19(1):34-43. PubMed ID: 26337538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of drug and administrative costs allowed by U.S. Private and public third-party payers for 3 intravenous biologic agents for rheumatoid arthritis.
    Wong BJ; Cifaldi MA; Roy S; Skonieczny DC; Stavrakas S
    J Manag Care Pharm; 2011 May; 17(4):313-20. PubMed ID: 21534642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment Patterns, Direct Cost of Biologics, and Direct Medical Costs for Rheumatoid Arthritis Patients: A Real-world Analysis of Nationwide Japanese Claims Data.
    Sugiyama N; Kawahito Y; Fujii T; Atsumi T; Murata T; Morishima Y; Fukuma Y
    Clin Ther; 2016 Jun; 38(6):1359-1375.e1. PubMed ID: 27101816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment Persistence and Healthcare Costs Among Patients with Rheumatoid Arthritis Changing Biologics in the USA.
    Chastek B; Chen CI; Proudfoot C; Shinde S; Kuznik A; Wei W
    Adv Ther; 2017 Nov; 34(11):2422-2435. PubMed ID: 29039054
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world Effectiveness of Biologic Disease-modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis After Etanercept Discontinuation in the United Kingdom, France, and Germany.
    Li N; Betts KA; Messali AJ; Skup M; Garg V
    Clin Ther; 2017 Aug; 39(8):1618-1627. PubMed ID: 28729087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors associated with the initiation of biologic disease-modifying antirheumatic drugs in Texas Medicaid patients with rheumatoid arthritis.
    Kim G; Barner JC; Rascati K; Richards K
    J Manag Care Spec Pharm; 2015 May; 21(5):401-7. PubMed ID: 25943001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.